Connect your AI

ANI Pharmaceuticals ANIP Treasury Stock

Treasury Stock at other companies

ViatrisVTRS

$1.01B+48.1%

Ultragenyx PharmaceuticalRARE

$10M+32.2%

United TherapeuticsUTHR

$5.44B+56.6%

PfizerPFE

$115.19B+0.2%

AptarGroupATR

$1.05B+55.6%

Other financials

Income statement

Revenue$237.5M+20.5%

Gross profit$143.9M+16.0%

Operating income$38.9M+48.5%

Net income$29.5M+88.1%

EPS (diluted)$1.28+85.5%

Balance sheet

Cash & equivalents$311.2M+108%

Total debt$305.3M-3.5%

Total equity$562.3M+34.3%

Total assets$1.4B+10.0%

Cash flow

Operating cash flow$58.4M+66.8%

CapEx$6.1M+146%

Free cash flow$52.3M+60.8%

Valuation

Market cap$1.88B+18.3%

Profitability

Gross margin60.8%+1.5pp

Operating margin13.4%—

Net margin10%+8.1pp

FCF margin20.7%+10.8pp

Returns & leverage

Return on equity18.8%+15.6pp

Debt / equity0.5×-0.2×

Current ratio3.1×+0.5×

Where this comes from

Reported directly by ANI Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:TreasuryStockCommonValue.

The official record: ANI Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about ANI Pharmaceuticals's treasury stock.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is ANI Pharmaceuticals's treasury stock?: ANI Pharmaceuticals (ANIP) reported treasury stock of $53M in Q1 2026.
How has ANI Pharmaceuticals's treasury stock changed year-over-year?: ANI Pharmaceuticals's treasury stock increased by 70.7% year-over-year, from $31.04M to $53M.
What is the long-term trend for ANI Pharmaceuticals's treasury stock?: Over 5 years (2020 to 2025), ANI Pharmaceuticals's treasury stock has grown at a 71.4% compound annual growth rate (CAGR), from $2.25M to $33.25M.
What does treasury stock mean?: Shares repurchased by the company and held in treasury, reducing equity. Recorded at cost and presented as a negative equity component.